Spleen
tyrosine kinase (Syk) is a protein that belongs to the family of
tyrosine kinases with an ability to initiate the inflammatory responses, by
connecting immune cell receptors to intracellular signaling pathways.
Therefore, Syk is an attractive target for improving the symptoms related to
acute and chronic inflammation.
In addition, the role of protein is recognized
as a promoter in various types of cancers ranging from leukemia to
retinoblastoma. Syk protein facilitates the phosphorylation of protein on
tyrosines and also involves in the B cell antigen receptor (BCR) signalling
pathways. There are several drugs that effectively inhibit the Syk kinase but
the off-target effect is a limiting factor. Currently, there are various Syk
inhibitors that prevent release of inflammatory cytokines in vitro and IgE-driven
mast cell degranulation.
Request to Get the Sample Pages at:
Levolta Pharmaceuticals Inc. is developing a drug candidate,
that acts as Syk inhibitor for the treatment of immunological diseases. Rigel
Pharmaceuticals Inc. is developing fostamatinib as a Syk inhibitor for the
treatment of chronic immune thrombocytopenia and autoimmune hemolytic anemia. Hutchison
China MediTech Limited is also developing HMPL-523 as a Syk inhibitor for the
treatment of cancer indications. Some of the companies having pipeline of Syk
inhibitor include Genosco Inc., Asana BioSciences LLC, and others.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of development,
with the detailed analysis of pipeline and clinical trials. Pipeline analysis
of drugs by phases includes product description and development activities
including information about clinical results, designations, collaborations,
licensing, grants, technology, and others.
No comments:
Post a Comment